User profiles for Maja Segedi

Maja Segedi

Clinical Assistant Professor
Verified email at vch.ca
Cited by 135

The role of intraperitoneal chemotherapy in the surgical management of pancreatic ductal adenocarcinoma: a systematic review

…, M Webb, M Parapini, L Sidéris, M Segedi… - Clinical & experimental …, 2021 - Springer
Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with poor prognosis,
particularly for patients with metastatic disease. Treatment for oligometastatic presentation …

Management of complex acute biliary Disease for the general surgeon: a narrative review

L Cadili, L Streith, M Segedi, AH Hayashi - The American Journal of …, 2023 - Elsevier
Acute gallbladder diseases are a common surgical emergency faced by General Surgeons
that can sometimes be quite complex. These complex biliary diseases require multifaceted …

Clinical consensus statement: Establishing the roles of locoregional and systemic therapies for the treatment of intermediate-stage hepatocellular carcinoma in …

…, A Mujoomdar, I Martins, E Dixon, M Segedi… - Cancer Treatment …, 2023 - Elsevier
Background Hepatocellular carcinoma (HCC) a leading cause of cancer mortality worldwide
and approximately one-third of patients present with intermediate-stage disease. The …

Minimally invasive hepatectomy is associated with decreased morbidity and resource utilization in the elderly

…, S Raman, CH Scudamore, SW Chung, M Segedi - Surgical …, 2020 - Springer
Background The aim of this study was to evaluate whether elderly patients undergoing
elective hepatectomy experience increased morbidity/mortality and whether these outcomes …

[HTML][HTML] Neoadjuvant therapy and major arterial resection for potentially reconstructable arterial involvement by stage 3 adenocarcinoma of the pancreas

…, K Tomiyama, A Tremblay, AM Fox, M Segedi… - HPB, 2019 - Elsevier
Background Stage 3 pancreatic ductal adenocarcinoma (PDAC) is defined by arterial
involvement. This study objective was to evaluate outcomes for patients with stage 3 PDAC with …

[HTML][HTML] Outcomes of liver transplant recipients with high MELD scores: an experience from a Canadian centre

…, S Chartier-Plante, M Segedi… - Canadian Journal of …, 2022 - ncbi.nlm.nih.gov
Background: The frequency with which patients with high Model for End-Stage Liver Disease
(MELD) scores undergo liver transplantation has been increasing. Canadian literature …

BRM polymorphisms, pancreatic cancer risk and survival

M Segedi, LN Anderson, O Espin‐Garcia… - … Journal of Cancer, 2016 - Wiley Online Library
Variant alleles of two promoter polymorphisms in the BRM gene (BRM‐741, BRM‐1321),
create MEF2D transcription binding sites that lead to epigenetic silencing of BRM, the key …

[HTML][HTML] Impact of surgical wait times on oncologic outcomes in resectable pancreas adenocarcinoma

…, J Li, S Desai, SW Chung, CH Scudamore, M Segedi… - HPB, 2020 - Elsevier
Background Timely surgical resection in patients with suspected or diagnosed pancreas
adenocarcinoma is an essential part of care. We hypothesized that longer surgical wait time …

Surgical complications of liver transplantation

C Tan-Tam, M Segedi, A Buczkowski… - AME Medical …, 2018 - amj.amegroups.org
After the first successful human liver transplant in 1967 by Dr. Thomas Starzl at the University
of Colorado Health Science Center, the techniques, medicine and technology continued to …

[HTML][HTML] The association between bacterobilia and the risk of postoperative complications following pancreaticoduodenectomy

…, A Mah, S Desai, S Chung, CH Scudamore, M Segedi… - HPB, 2022 - Elsevier
Background Pre-operative biliary bacterial colonisation (bacterobilia) is considered a risk
factor for infectious complications after pancreaticoduodenectomy (PD). This study aimed to …